The Outsourcing Facilities Association and compounding pharmacy FarmaKeio Superior Custom Compounding filed a lawsuit following the FDA’s initial announcement, arguing that the shortages were ongoing and that the decision would limit access to essential medicines.
After reevaluating the situation, the agency said it does not plan to take action against compounding pharmacies that violate the law requiring a drug’s inclusion on the FDA shortage list for compounding.
Tirzepatide, the main ingredient of both medicines, fell into short supply because of high demand. Similar GLP-1 medications — semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide (Saxenda, Victoza) and dulaglutide (Trulicity) — remain on the FDA’s drug shortage list.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.